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Other names: axil (mostly in rat); conductin; 
DKFZp781B0869 (single database entry only); 




The AXIN2 gene spans about 35 kbp including 10 
coding exons and 3 non-coding 5' exons (E0a, 0b and 
0c; see above). Nearby genes: about 70 kbp upstream is  
CCDC46 (coiled-coil domain containing 46), about 300 
kbp downstream is RGS9 (regulator of G-protein 
signalling 9). In addition, there is a putative gene that 
overlaps the AXIN2 non-coding 5' exons and coding  
 
exon 1 (E1) and is transcribed from the same strand 
(Gnomon model hmm119498); there is no published 
data on whether this is actually expressed. 
Transcription 
Transcription occurs from three separate promoters 
leading to initiation at each of the three non-coding 5' 
exons. mRNAs are spliced so that each non-coding 
exon is expressed separately, rather than in 
combinations. It is unclear whether transcription can 
initiate at the first coding exon (E1). Promoters can be 
activated by TCF transcription factors binding at 
multiple sites and by E2F1 binding at up to 4 sites, 
although E2F1 can also induce transcription in the 
absence of consensus sites. It has been reported that 







The 5' end of the human AXIN2 gene. An alignment of human genomic DNA (top line) with the 5' end of different Axin2 mRNA variants. 















Human Axin2 is an 843 amino acids protein (777 
amino acids from delta exon 6 mRNAs) containing an 
RGS domain (regulator of G protein signalling; amino 
acids 81-200), a GSK-3 beta binding domain (amino 
acids 327-413), a beta-catenin binding domain (amino 
acids 413-476), and a DIX domain (domain in 
dishevelled and axin; amino acids 761-843). 
Expression 
Expression appears to be ubiquitous in adult tissues 
(although at differing levels), but is limited to specific 
regions during embryonic development. Expression is 
regulated at multiple levels including transcription, 
mRNA stability, translation and protein stability. 
Localisation 
Axin2 protein has been localised to the cytoplasm, the 
nucleus and the mitotic spindle. 
Function 
Molecular functions: 
1) Axin2 acts as a negative regulator of canonical 
Wnt/TCF signalling by enhancing formation of the 
beta-catenin destruction complex. Since expression of 
Axin2 is itself activated by canonical Wnt/TCF 
signalling, this results in a negative feedback-loop that 
restricts TCF activity. 
2) Axin2 may influence TCF activity by re-localising 
beta-catenin to the cytoplasm. 
3) Activity of the GSK-3 beta target snail1 can be 
regulated by Axin2's ability to influence the nucleo-
cytoplasmic localisation of GSK-3 beta. 
4) Axin2 binds polo-like kinase 1 (PLK1) during 
mitosis and influences the accuracy of chromosome 
segregation. 
Cellular/physiological functions: 
1) Axin2 expression oscillates during early 
embryogenesis in response to Wnt3a this is required to 
achieve correct the temporal TCF activity to allow 
somatogenesis. 
2) A requirement for Axin2 for correct calvarial 
morphogenesis and craniosynostosis has been revealed 
in Axin2 -/- mice. 
3) Axin2 appears to act as a tumour suppressor, and 
somatic mutations have been seen in many different 
tumour types (see below). 
Homology 
Axin2 is 44% identical to axin in mice and knock-in 
experiments suggest that the proteins can be 
functionally equivalent. 
Mutations 
Note: A large number of different mutations in the 
AXIN2 gene have been identified. In many cases (but
not all) these lead to premature translational 
termination and protein truncation. Truncated Axin2 
protein is more stable than the wild type, while thre 
has been speculation that the mRNA may be less stable. 
Germinal 
Heterozygous germ line mutations in exon 7 that lead 
to premature termination are associated with familil 
tooth agenesis and a predisposition to colorectal cancer. 
Further germ line polymorphisms associated with 
familial tooth agenesis have been identified in exons 2 
and 7. A polymorphism within exon 1 has been 
identified that is associated with risk of lung caner. 
Many other polymorphisms that have yet to be 
associated with any function have been detected. 
Somatic 
The genomic region containing the AXIN2 gene shows 
loss of heterozygosity and re-arrangements in a variety 
of cancers. In addition somatic point mutations and 
deletions have been identified in colorectal cancer, 
hepatocellular carcinomas, ovarian endometrioid 
adenocarcinomas and hepatoblastomas. Many of these 
mutations/deletions result in translation of truncated 
proteins that are likely to be functionally inactive, 
although one report has suggested that these truncaed 
proteins have a dominant negative activity. 
Implicated in 
Colorectal cancer (CRC) 
Oncogenesis 
Axin2 is often over-expressed in CRC as a result of the 
deregulation of canonical Wnt/beta-catenin signallig 
that is an early event in CRC development (usually 
caused by mutations/deletions in APC or beta-catenin). 
Somatic inactivating mutations within Axin2 have been 
reported in CRC and theoretically these could 
contribute to further deregulation of Wnt/beta-catenin 
suggesting that Axin2 is a tumour suppressor. However 
mutations have only been seen in microsatellite 
unstable tumours and often within regions of mono-
nucleotide repeats (exon 7), hence whether Axin2 
mutations are cause or effect in these tumours remains 
undetermined. In support of Axin2's role as a tumour 
suppressor are observations that Axin2 is silenced by 
promoter methylation in many microsatellite unstable 
tumours.  
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As discussed above, heterozygotes for some germ line 
mutations in AXIN2 are predisposed to CRC although 
this seems to be involved with only a very small 
proportion of familial colorectal cancer. 
Other cancers (hepatocellular 
carcinomas, hepatoblastomas, ovarian 
endometrioid adenocarcinomas) 
Oncogenesis 
Somatic mutations in Axin2 have been detected in a 
range of cancer types. It is usually assumed that these 
lead to partial inactivation of Axin2 function thereby 
deregulation of canonical Wnt/beta-catenin signallig. 
In most cases this has not formally been demonstrated, 
and the contribution of Axin2 mutations to any putative 
change in Wnt/beta-catenin activity and to the 
development of these cancers remains mostly unclear. 
Familial Tooth Agenesis (see above) 
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